Clinical experience with a new transvenous atrial lead.
Although systems using atrial pacemakers offer potential clinical advantages for many patients now receiving ventricular devices, atrial systems have been used in less than 1% of the implantations of permanent pacemakers. The unavailability of clinically successful, easily positioned atrial leads is regarded as the most significant factor in the underutilization of atrial pacing systems. A permanent transvenous atrial lead has been developed and has performed well in 16 months of evaluation in 28 patients. Acute thresholds for voltage at a pulse width of 1 msec ranged from 0.40 v to 2.0 v (average, 1.1 v). Acute peak-to-peak amplitudes of the atrial electrogram were notably high, ranging from 2.5 mv to 7.5 mv (average, 5.1 mv) as measured oscilloscopically. Intermittent failure of sensing occurred in three patients during the period immediately after implantations. Spontaneous dislodgment of the lead from the right atrial appendage occurred in two patients. Atrial sensing and pacing functions remained intact in the first case, and no revision was performed. The lead was repositioned in the second patient and has remained in good position. No complications relating to the lead have been noted in the remaining patients.
D000328:Adult; D000368:Aged; D000818:Animals; D001146:Arrhythmia, Sinus / Q000628:therapy*; D004567:Electrodes, Implanted / Q000592:standards; D005260:Female; D005500:Follow-Up Studies; D006325:Heart Atria; D006801:Humans; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods*